News|Articles|November 17, 2026

Selinexor Combo Advances in Myelofibrosis FDA Review

Author(s)Matt Flowers
Fact checked by: Sabrina Serani
Listen
0:00 / 0:00

Key Takeaways

  • FDA sNDA filing targets the potential first approved combination regimen in myelofibrosis: selinexor (XPO1 inhibitor) plus ruxolitinib, with regulatory action expected by June 28, 2027.
  • SENTRY met the SVR35 coprimary endpoint at week 24 (49.8% vs 28.0%; OR 2.58; P<.0001), with durable and early separation across additional timepoints.
SHOW MORE

The FDA accepted a supplemental application for selinexor plus ruxolitinib in myelofibrosis, setting a June 28, 2027, target action date based on phase 3 SENTRY findings.

The FDA has accepted a supplemental new drug application (sNDA) for selinexor (Xpovio) in combination with ruxolitinib (Jakafi) for the treatment of patients with myelofibrosis. The application is supported by findings from the phase 3 SENTRY trial (NCT04562389), which demonstrated significantly improved spleen volume reduction with the combination vs ruxolitinib alone. The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date of June 28, 2027.¹

If approved, selinexor plus ruxolitinib could become the first approved combination therapy for patients with myelofibrosis, a rare hematologic malignancy characterized by bone marrow fibrosis, impaired blood cell production, splenomegaly, and progressive anemia.

Selinexor is an oral inhibitor of XPO1, a nuclear export protein involved in regulating the movement of proteins between the nucleus and cytoplasm. The drug is FDA approved in combination regimens for adults with multiple myeloma. Ruxolitinib, a JAK1/JAK2 inhibitor, is an established treatment for myelofibrosis.

SENTRY Findings Support the FDA Application

The sNDA is primarily supported by results from SENTRY, a randomized, double-blind, placebo-controlled phase 3 trial evaluating selinexor plus ruxolitinib vs placebo plus ruxolitinib in patients with JAK inhibitor–naive myelofibrosis. The study enrolled 353 patients who were randomized 2:1 to receive once-weekly selinexor 60 mg plus ruxolitinib or placebo plus ruxolitinib.²

The trial included 2 coprimary end points: spleen volume reduction of at least 35% (SVR35) at week 24 and change in absolute total symptom score (Abs-TSS) over 24 weeks relative to baseline.

At week 24, SVR35 was achieved in 49.8% of patients receiving selinexor plus ruxolitinib (n = 235) compared with 28.0% of those receiving placebo plus ruxolitinib (n = 118). This represented an odds ratio of 2.58 (95% CI, 1.60-4.17; P < .0001), meeting the spleen volume reduction coprimary end point.²

The improvement in spleen volume reduction was also observed at earlier and later assessments. At week 12, SVR35 rates were 49.4% with the combination vs 20.3% with ruxolitinib alone. At week 36, the respective rates were 46.9% and 23.0%. Additionally, the proportion of patients achieving SVR35 at any time during the study was 67.7% vs 44.9%, respectively.

However, the combination did not meet the second coprimary end point of symptom improvement. At week 24, mean Abs-TSS reductions were 9.9 points with selinexor plus ruxolitinib and 10.9 points with placebo plus ruxolitinib. The adjusted mean difference was 0.97 (95% CI, −1.07 to 3.02; P = .825), indicating no statistically significant difference between treatment groups.

Safety and Survival Findings

The SENTRY findings also demonstrated differences in treatment-related adverse events between the 2 groups. Grade 3 or higher treatment-emergent adverse events occurred in 70.1% of patients receiving selinexor plus ruxolitinib vs 50.0% receiving placebo plus ruxolitinib. Adverse events leading to treatment discontinuation were reported in 14.5% of patients in the combination arm and 8.6% of patients in the control arm.²

The most frequently reported adverse events with the combination included thrombocytopenia (59%), anemia (57%), nausea (57%), constipation (32%), neutropenia (27%), and fatigue (26%). Serious treatment-emergent adverse events occurred in 26.9% of patients receiving selinexor plus ruxolitinib vs 24.1% receiving placebo plus ruxolitinib.

An early overall survival signal also favored the combination. At the data cutoff, deaths had occurred in 4.7% of patients in the selinexor arm compared with 10.2% in the control arm (HR, 0.43; 95% CI, 0.19-1.00; nominal 1-sided P = .022). However, investigators characterized these findings as immature, with median follow-up of approximately 11 months.

"Selinexor offers a differentiated mechanism of action and, if approved, selinexor plus ruxolitinib could become the first approved combination therapy for patients with myelofibrosis," Reshma Rangwala, MD, PhD, chief medical officer and head of research at Karyopharm, said in the news release announcing the FDA's acceptance of the application.

REFERENCES
1. Karyopharm announces FDA acceptance of supplemental new drug application for XPOVIO (selinexor) plus ruxolitinib for the treatment of patients with myelofibrosis. Karyopharm Therapeutics Inc. News release. November 17, 2026. Accessed November 17, 2026. https://tinyurl.com/2ttkapjf
2. Mascarenhas J, Ali H, Al-Ali H, et al. Selinexor plus ruxolitinib in Janus kinase inhibitor–naïve myelofibrosis: phase III SENTRY trial. J Clin Oncol. 2026;44(22):2098-2109. doi:10.1200/JCO-26-01080

Related to this article